Thank you, Umbrex, for recognizing Luminary Group as one of the Top Pharmaceutical Consulting Firms! Umbrex has thoughtfully compiled this list based on extensive industry experience, discussions with industry leaders, and comprehensive secondary research. These leading consulting firms specialize in various sectors of the pharmaceutical industry, including clinical development, digital health innovation, pharmacovigilance, strategic planning, market access, product lifecycle management, and supply chain and manufacturing. Many also bring expertise in regulatory compliance and Health Economics and Outcomes Research (HEOR). Notably, many Umbrex consultants have prior experience working with most of the firms highlighted on this list. https://lnkd.in/eHeptiWE
About us
Luminary Group is a international business consultancy focused on the life sciences and pharmaceutical sectors. Headquartered at St Magnus House, 3 Lower Thames Street, Central London, EC3R 6HD, we deliver comprehensive services in three key areas. Luminary Executive: Specializing in C-suite to Director-level appointments, we identify top talent for positions including Chairman, Board members, CEO, CCO, COO, AVP to Director level. Luminary Staffing: We provide both temporary and permanent staffing solutions tailored to meet the commercial, project management, medical, biometrics, software and operational needs of our clients. Luminary Consulting: Offering high-quality services in medical writing, regulatory affairs, quality assurance, pharmacovigilance, and data science for the medical and pharmaceutical industries. We also provide strategic partnerships to accelerate growth through Recruitment Process Outsourcing (RPO) and Functional Service Provider (FSP) services. Lastly, our advisory services assist in data partnerships, leveraging our extensive network of leading RWE, RWD, and AI enterprises across the US and Europe, and provide guidance for business collaborations with biotechnology firms and navigating mergers and acquisitions. Our expertise includes Real World Evidence (RWE), eClinical solutions, Artificial Intelligence (AI), Biotechnology, Consulting, and Medical Devices. Operating globally with a presence in the USA, Europe, APAC, and the Middle East, we take pride in our exclusive talent pool, ranging from C-Suite to Managerial levels, and our partnerships with returning clients and candidates. Our collaborations extend across a diverse range of companies, from corporate giants to innovative start-ups. For more information, please visit our website: www.luminarygroup.co.uk.
- Website
-
www.luminarygroup.co.uk
External link for Luminary Group
- Industry
- Business Consulting and Services
- Company size
- 11-50 employees
- Headquarters
- City of London
- Type
- Privately Held
- Founded
- 2023
- Specialties
- Executive Search, Headhunting, Consulting, Life Sciences, Pharmacovigilence, Regulatory Affairs, CMC, Biotechnology, Diagnostics, CRO, Clinical Trials, Cell & Gene Therapy, Machine Learning, Real World Evidence, Real World Data, eClinical, eCOA, RPO, FSP, Corporate Development, Partnerships, Data Partnerships, RWE, RWD, and Artificial Intelligence
Locations
-
Primary
Get directions
City of London , GB
-
Get directions
4th St N, STE 300
7901
St. Petersburg, FL , 33702, US
Employees at Luminary Group
Updates
-
𝗕𝗶𝗼𝗡𝗧𝗲𝗰𝗵 𝘀𝗲𝘁𝘁𝗹𝗲𝘀 𝘄𝗶𝘁𝗵 𝗡𝗜𝗛, 𝗨𝗣𝗲𝗻𝗻 𝗶𝗻 𝗖𝗼𝘃𝗶𝗱 𝘃𝗮𝗰𝗰𝗶𝗻𝗲 𝗱𝗶𝘀𝗽𝘂𝘁𝗲𝘀 𝗮𝗻𝗱 𝘄𝗶𝗹𝗹 𝗽𝗮𝘆 𝗿𝗼𝘆𝗮𝗹𝘁𝗶𝗲𝘀 BioNTech SE has entered into settlement agreements with the NIH and the University of Pennsylvania marking a key turning point in the long-running disputes and the … https://lnkd.in/d4C2Fx7n
BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties
endpts.com
-
𝗢𝗹𝘆𝗺𝗽𝘂𝘀 𝗶𝘀 𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝗳𝗼𝗿 𝗮 𝗻𝗲𝘄 𝗖𝗘𝗢 Olympus EMEA has engaged a global executive recruitment firm to assist a board search committee in evaluating CEO candidates. https://lnkd.in/d-iNsSJA
Olympus is looking for a new CEO
https://www.massdevice.com
-
𝗪𝘂𝗫𝗶 𝗔𝗽𝗽𝗧𝗲𝗰 𝘄𝗶𝗹𝗹 𝘀𝗲𝗹𝗹 𝗰𝗲𝗹𝗹 𝗮𝗻𝗱 𝗴𝗲𝗻𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗯𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝘁𝗼 𝗽𝗿𝗶𝘃𝗮𝘁𝗲 𝗲𝗾𝘂𝗶𝘁𝘆 𝗳𝗶𝗿𝗺 WuXi AppTec will sell its Advanced Internet Technologies, Inc. ("AIT, Inc.") unit to the US private equity firm Altaris for an undisclosed amount, a long-anticipated move after months of … https://lnkd.in/dmF-wBv7
WuXi AppTec will sell cell and gene therapy business to private equity firm
endpts.com
-
𝗦𝗮𝗻𝗼𝗳𝗶 𝗽𝗮𝘆𝘀 𝗦𝗞 𝗯𝗶𝗼𝘀𝗰𝗶𝗲𝗻𝗰𝗲 €𝟱𝟬𝗠 𝗮𝘀 𝗰𝗵𝗶𝗹𝗱𝗿𝗲𝗻'𝘀 𝗽𝗻𝗲𝘂𝗺𝗼𝗰𝗼𝗰𝗰𝗮𝗹 𝘃𝗮𝗰𝗰𝗶𝗻𝗲 𝗲𝗻𝘁𝗲𝗿𝘀 𝗽𝗵𝗮𝘀𝗲 𝟯 Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal conjugate vaccine program into phase 3. https://lnkd.in/dueSZB6r
Sanofi pays SK bioscience €50M as children's pneumococcal vaccine enters phase 3
fiercebiotech.com
-
𝗦𝗮𝗺𝘀𝘂𝗻𝗴 𝗜𝗻𝘃𝗲𝘀𝘁𝘀 𝗶𝗻 𝗚𝗲𝗻𝗲𝗿𝗮𝘁𝗲: 𝗕𝗶𝗼𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀 The Samsung Biologics has invested in Generate:Biomedicines as part of its efforts to drive growth and innovation in the biopharmaceutical sector. https://lnkd.in/dbPdPuSY
Samsung Invests in Generate: Biomedicines
https://www.contractpharma.com
-
Merry Christmas from the team at Luminary Group! #christmas #happyholiday
-
-
𝗙𝗗𝗔 𝗔𝗽𝗽𝗿𝗼𝘃𝗲𝘀 𝗟𝗶𝗹𝗹𝘆’𝘀 𝗭𝗲𝗽𝗯𝗼𝘂𝗻𝗱 𝗳𝗼𝗿 𝗦𝗹𝗲𝗲𝗽 𝗔𝗽𝗻𝗲𝗮 Eli Lilly and Company received approval from the FDA for Zepbound (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. https://lnkd.in/dJD6HFSY
FDA Approves Lilly’s Zepbound for Sleep Apnea
https://www.contractpharma.com
-
𝗔𝗯𝗯𝗼𝘁𝘁, 𝗗𝗲𝘅𝗰𝗼𝗺 𝘀𝗲𝘁𝘁𝗹𝗲 𝗴𝗹𝗼𝗯𝗮𝗹 𝗖𝗚𝗠 𝗽𝗮𝘁𝗲𝗻𝘁 𝗹𝗶𝘁𝗶𝗴𝗮𝘁𝗶𝗼𝗻 Abbott and Dexcom two leaders in the continuous glucose monitor market, today struck a settlement agreement for ongoing patent litigation https://lnkd.in/dcHc7X59
Abbott, Dexcom settle global CGM patent litigation
https://www.massdevice.com
-
𝗡𝗼𝘃𝗼 𝗡𝗼𝗿𝗱𝗶𝘀𝗸’𝘀 𝗼𝗻𝗰𝗲-𝗱𝗮𝗶𝗹𝘆 𝗵𝗲𝗺𝗼𝗽𝗵𝗶𝗹𝗶𝗮 𝗱𝗿𝘂𝗴 𝗔𝗹𝗵𝗲𝗺𝗼 𝗮𝗽𝗽𝗿𝗼𝘃𝗲𝗱 𝗶𝗻 𝗨𝗦 Novo Nordisk finally won US approval for its hemophilia drug Alhemo following the product’s rejection by the FDA last year. https://lnkd.in/dDsCrMNe
Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US
endpts.com